Test Price
850 AEDโ Home Collection Available
FISH for inv(16) / CBFB Gene Rearrangement Test in UAE | 850 AED | DHA Licensed
Executive Summary & Core Metrics
This advanced genetic test provides definitive diagnosis of acute myeloid leukemia (AML) subtype M4Eo using fluorescence in-situ hybridization (FISH) technology, processed under strict DHA-accredited protocols at DNA Labs UAE.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital Extraction Only โ Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Complimentary post-test telephonic clinical correlation by DHA-certified genetics specialists.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The FISH for inv(16)/CBFB gene rearrangement detects specific chromosomal abnormalities associated with acute myeloid leukemia, particularly acute myelomonocytic leukemia with abnormal eosinophils (AML-M4Eo). This fluorescence in-situ hybridization assay directly visualizes the CBFB gene break-apart or fusion signals on interphase cells from blood or bone marrow, delivering results within 4 working days.
| Feature | Our FISH inv(16)/CBFB Test | Conventional Karyotyping |
|---|---|---|
| Precision | Single-cell resolution, detects cryptic rearrangements | Limited to metaphase cells; may miss submicroscopic inversions |
| Methodology | FISH using LSI CBFB break-apart probe (interphase/metaphase) | G-banding karyotype on cultured cells |
| Turnaround Time | 4 working days | 7โ14 days |
| Sample Requirements | 3 mL whole blood or 2 mL bone marrow in sodium heparin (green top), non-frozen | Larger volume, sterile collection, transport at room temp |
Physician Insight & Safety Protocols
โAs a DHA-licensed Consultant Medical Genetics, I emphasize that while the FISH inv(16)/CBFB test provides definitive genetic evidence, it must always be correlated with morphology, immunophenotyping, and clinical context. A positive result supports AML-M4Eo diagnosis but does not replace full diagnostic workup. Please use this test as part of a comprehensive evaluation.โ โ Lina Osama Zaki Quteineh, DHA Registration ID: 9294403.
Advisory on Medication and Treatment
โ Medication Warning
Do not discontinue prescribed chemotherapy or any medication without consulting your treating physician. Interpretation of this genetic test should be done by a qualified oncologist or hematologist.
Exclusion Criteria & Emergency Red Flags
- Severe bleeding tendency or platelet count < 20,000/ฮผL (venipuncture risk).
- Active systemic infection with hemodynamic instability โ postpone sampling.
- Inability to provide mandatory Chromosome & FISH Analysis Requisition Form (Form 17).
- Sample frozen or exposed to temperature extremes โ testing invalidated.
If you experience fever, uncontrolled bleeding, or sudden neurological changes after bone marrow aspiration, seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What does the FISH inv(16)/CBFB test detect?
This specifically identifies inversions or translocations involving chromosome 16 and the CBFB gene, which are defining genetic abnormalities in acute myeloid leukemia subtype M4Eo.
2. How should I prepare for the sample collection?
No fasting is required. You must complete the mandatory Chromosome & FISH Analysis Requisition Form (Form 17). The sample must be collected in a sodium heparin green-top tube and kept at room temperature without freezing. Collection takes place in a hospital setting under sterile conditions.
3. What does a positive result mean for my treatment?
A positive result confirms the presence of the inv(16)/CBFB rearrangement, which classifies AML as favorableโrisk and guides targeted therapy decisions, including potential use of gemtuzumab ozogamicin. Your oncologist will interpret the result in the context of your full clinical picture.
4. How long does it take to get results?
Results are available within 4 working days from receipt of the sample. A detailed genetic report is provided with clinical correlation guidance.
UAE Regulatory & Data Privacy Adherence
This test is conducted under the regulatory framework of the Dubai Health Authority (DHA Facility License No. 1143). All personal data handling complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | FISH for inv(16) / CBFB Gene Rearrangement |
| Price (AED) | 850 AED |
| Turnaround Time | 4 working days |
| Sample Type / Matrix | Whole blood (3 mL) or Bone marrow (2 mL) in sodium heparin (green top) โ Hospital extraction only |
| Methodology Used | Fluorescence in-situ hybridization (FISH) with LSI CBFB break-apart probe |
| ICD-10-CM Code | C92.5 (Acute myelomonocytic leukemia) |
| LOINC Code | 18022-7 (CBFB gene rearrangement) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians